Journal
BIOMEDICAL REPORTS
Volume 19, Issue 1, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/br.2023.1629
Keywords
fucoxanthin; gemcitabine; combination therapy; pancreatic cancer cells; nutraceutical
Categories
Ask authors/readers for more resources
The combination of fucoxanthin, a marine carotenoid, with gemcitabine, a chemotherapeutic agent, enhances the inhibitory effect on pancreatic cancer cells without cytotoxicity to non-cancer cells. This suggests that fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.
Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available